Search

Chinese
Resource Library / Strategies and Solutions for Early Phase Formulation Development and CTM Manufacturing

webinar

Strategies and Solutions for Early Phase Formulation Development and CTM Manufacturing

In this webinar, we discuss the strategies to overcome challenges during formulation development, various technologies available for formulation development, and Frontage CMC's unique capabilities.

Resource Preview

Resources to Consider

Left arrow
Nonclinical Vehicle Formulations:HP-β-CD (Hydroxypropyl-Beta-Cyclodextrin) & The Risk of Hemolysis
poster

Nonclinical Vehicle Formulations:HP-β-CD...
Beta-cyclodextrin is a commonly used excipient in nonclinical vehicle formulations. In a r...
Access Resource
Evaluating the feasibility of lyophilization for oral formulation development of monoclonal antibodies (mAbs)​
poster

Evaluating the feasibility of lyophilization for oral formulation...
Objective: To develop a stable lyophilized non-invasive oral formulation of monoclonal ant...
Access Resource
Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug Delivery System for Cannabinoids
poster

Development of Stable Nanoemulsion Formulation as an Ophthalmic Drug...
This study is aimed at developing a Nanoemulsion formulation of a poorly water-soluble and...
Access Resource
Clinical Study of Abuse-Deterrent Formulation to Suppress Release of Hydrocodone
case-study

Clinical Study of Abuse-Deterrent Formulation to Suppress Release of...
A number of the abuse-deterrent formulations in development and available on the market ut...
Access Resource
Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using the Simoa HD-X platform
poster

Qualification of the Quanterix Phospho-Tau 217 (pTau-217) assay using...
Alzheimer’s disease (AD) is a neurodegenerative disorder which stands as one of the most...
Access Resource
Companion Diagnostics for Alzheimer’s Disease
poster

Companion Diagnostics for Alzheimer’s Disease
Method Validation of Phospho-Tau217 (pTau-217) Quantitation Using the Quanterix Simoa™ ...
Access Resource
Development and validation of an LC-MS/MS method for the quantification of fascin proteins in human serum
journal

Development and validation of an LC-MS/MS method for the...
Fascin is an actin-bundling protein that has been linked to tumor cell migration, invasion...
Access Resource
A Competitive Ligand-binding Assay for the Detection of Neutralizing Antibodies Against XTMAB-16
poster

A Competitive Ligand-binding Assay for the Detection of Neutralizing...
Frontage develops a full validation of the XTMAB-16 NAb (neutralizing antibody) assay with...
Access Resource
Validation of a 384 gene hybridization capture-based pharmacogenomics NGS panel: sensitivity, specificity, accuracy, and reproducibility in calling star alleles for drug metabolism genes
poster

Validation of a 384 gene hybridization capture-based pharmacogenomics...
​Frontage has developed a next-generation sequencing (NGS)-based method to rapidly deter...
Access Resource
Immunoassays for Drug Discovery
fact-sheet

Immunoassays for Drug Discovery
Frontage supports early drug discovery with various immunoassays for proteins and therapeu...
Access Resource
Testing of Carryover & After MRD Benchtop Stability for Pharmacokinetic Method Validation in Gyrolab Immunoassay Platform
white-paper

Testing of Carryover & After MRD Benchtop Stability for...
In this white paper, we show testing of two critical parameters for the method validation ...
Access Resource
Utilizing Ligand Binding Assays (LBA) and Critical Reagents for Drug Development
panel-discussion

Utilizing Ligand Binding Assays (LBA) and Critical Reagents for Drug...
Critical reagents – the key components used in LBA – are central to ensuring the consi...
Access Resource
Right arrow